Urothelial-type mucinous adenocarcinoma of the prostate: A case report and review of the literature.
- Author:
Yong-shun GUO
;
Su-mei GAO
;
Ming-rong ZHANG
;
Ju-min ZHANG
;
Yun-jiang ZANG
;
Hong-kai LU
- Publication Type:Case Reports
- MeSH: Adenocarcinoma, Mucinous; metabolism; pathology; therapy; Humans; Keratins; metabolism; Male; Middle Aged; Neoplasm Proteins; metabolism; Prognosis; Prostatectomy; Prostatic Neoplasms; metabolism; pathology; therapy; Racemases and Epimerases; metabolism
- From: National Journal of Andrology 2016;22(3):241-245
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the clinical manifestations, pathological characteristics, and treatments of urothelial-type mucinous adenocarcinoma of the prostate (UMAP).
METHODSWe reported a case of UMAP, reviewed relevant literature, and analyzed the clinicopaothological features, diagnosis, treatment, and prognosis of the disease.
RESULTSThe patient was a 60-year-old male and underwent transurethral resection of the prostate for dysuria. Postoperative pathology indicated mucinous adenocarcinoma and sigmoidoscopy revealed no primary colon cancer. Immunohistochemical staining showed the negative expressions of PSA and P504s and positive expressions of CK7, CK34 β E12, CK20, and CDX2. Thus UMAP was confirmed and treated by intensity-modulated radiotherapy. Then the patient was followed up for 30 months, which showed desirable therapeutic result, with neither local progression nor distant metastasis.
CONCLUSIONUMAP has a bad prognosis and its diagnosis depends on pathological and immunohistocchemical examinations. It responds well to radical prostatectomy but is not sensitive to endocrine therapy. Radiotherapy can be considered for those who are not fit to receive radical prostatectomy.